Please find attached Investor Presentation for the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026.
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 28 Apr 2026, 09:37 AM IST · BSE ID: e4e2c153-fb90-4950-af02-b235e9b2b9f8
View Original BSE Filing (PDF)
💡
In Simple Terms
Fabtech Technologies reported FY26 profits of ₹38.36 Crore with revenue growth of 28.4%, backed by ₹900+ Crore in secured orders across Middle East and Africa.
🤖 AI Summary
- FY26 Consolidated Total Income ₹431.33 Crore, up 28.4% YoY; Net Profit ₹38.36 Crore after exceptional items adjustment
- Order book ₹900+ Crore as of March 31, 2026, driving forward revenue visibility and execution momentum
- UAE largest market at ₹126.66 Crore; Kenya revenue surged 236% YoY to ₹43.42 Crore; KSA at ₹82.72 Crore
- Cash and bank balances increased to ₹208.57 Crore from ₹35.01 Crore; debt reduced from ₹54.09 Crore to ₹42.20 Crore
- Won three major projects: West Africa OSD (USD 7.05 million), Saudi Arabia vaccine (USD 7.8 million), North Africa veterinary (₹49-52 Crore)
🔢 Key Numbers — exact figures from BSE filing, not rounded
FY26 Consolidated Total Income
₹431.33 Crore
+28.4%
FY26 Net Profit (PAT)
₹38.36 Crore
Consolidated Order Book
₹900+ Crore
FY26 EBITDA
₹55.56 Crore
+18.29%
Cash & Bank Balances
₹208.57 Crore
+495.7%
Current Borrowings
₹42.20 Crore
UAE Revenue
₹126.66 Crore
Kenya Revenue
₹43.42 Crore
+236%
West Africa OSD Project Value
USD 7.05 million (~₹63.6 Crore)
Saudi Arabia Animal Vaccine Project Value
USD 7.8 million (~₹65.5 Crore)
North Africa Veterinary Facility Value
₹49–52 Crore
Operating Cash Flow FY26
₹0.48 Crore
🏢 How This Affects the Company
Revenue pipeline strengthened by ₹900+ Crore consolidated order book, with geographic diversification into Kenya (236% YoY growth) and new sectors—animal health and vaccines—broadening market exposure beyond core pharmaceutical manufacturing.
Cash position improved substantially to ₹208.57 Crore from ₹35.01 Crore; operating cash flow swung positive to ₹0.48 Crore in FY26 from negative ₹(36.15) Crore in FY25; debt reduction from ₹54.09 Crore to ₹42.20 Crore strengthens balance sheet.
Expanded execution platform through three major strategic project wins in Africa and Saudi Arabia; operating resilience demonstrated despite logistics disruptions and freight challenges, with minimal performance impact.
High receivables in UAE (₹37.10 Crore) and KSA (₹61.38 Crore) tied to project scale and standard collection cycles; international geographic concentration creates foreign exchange and geopolitical exposure.
👥 What This Means For Shareholders
✅
Action Required
No immediate action required. Review investor presentation for project execution timelines and order book composition.
👤
Who Is Affected
All equity shareholders benefit from strengthened balance sheet (cash ₹208.57 Crore, debt reduced to ₹42.20 Crore) and order visibility. International operations expose all shareholders to foreign exchange fluctuations.
🔍
Management Signal
Management prioritizes geographic expansion and sector diversification beyond core pharma—animal health, vaccines, veterinary facilities—indicating strategy to reduce single-sector dependency.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results: verify revenue run-rate and order book conversion into topline growth
North Africa veterinary facility completion: track Q1 FY27 target delivery and EU-GMP certification status
Kenya market stability: monitor if 236% YoY growth sustains or normalizes in FY27 quarterly filings
MEDIUM RISK
High receivables concentration in UAE (₹37.10 Crore) and KSA (₹61.38 Crore); 78% revenue from MENA/GCC/ECO zones creates geopolitical and foreign exchange exposure.
💡 Investor Takeaway
FY26 Consolidated Total Income reached ₹431.33 Crore (up 28.4% YoY) with Net Profit ₹38.36 Crore. Order book of ₹900+ Crore provides multi-year revenue visibility. Cash position strengthened to ₹208.57 Crore; debt reduced to ₹42.20 Crore. Geographic diversity across UAE, KSA, and Kenya reduces concentration risk.
⚖️ Strengths & Concerns
✅ Positives
- Strong order book ₹900+ Crore provides multi-year revenue visibility; FY26 Total Income grew 28.4% to ₹431.33 Crore
- Cash position surged to ₹208.57 Crore from ₹35.01 Crore; operating cash flow improved from negative to positive in FY26
⚠️ Concerns
- High receivables concentration: UAE ₹37.10 Crore and KSA ₹61.38 Crore reflect extended collection cycles typical of large project execution
- Kenya's 236% YoY revenue growth to ₹43.42 Crore represents expansion into nascent markets with unproven long-term stability